These latest contraceptives with women’s names are at the centre of controversy in France due claims that they produce serious side effects in women.
The concern started in December, when Marion Larat filed a complaint against la Bayer due to a brain haemorrhage she suffered in 2006 that left her disabled.
The young woman of 25 claims that the Méliane contraceptive pill, produced by that chemical pharmaceutical company with a subsidiary in France, is responsible for the brain damage.
After Larat, another 14 women made claims against different brands of tablets for producing health problems.
The controversy increased when the French National Agency for Medicines and Health Products Safety (ANSM) confirmed the death of four women in the last 25 years due to deep vein thrombosis related to the consumption of Diane 35, which was also related to 120 other cases.
This pill is indicated for acne treatment and alopecia, but it is also used as a contraceptive.
Nevertheless, the health authorities consider that the assumed benefits of the drug are inferior to the risks associated to thrombosis, and besides, its efficacy as a contraceptive has not been proven by appropriate clinical trials.
In the meantime, the Health minister, Marisol Touraine, ordered doctors to limit the prescriptions for other third and fourth generation drugs, and announced the suspension of their financing as of March.
Tourraine also requested that the European Union kept the prescription of this type of combined oral contraceptive, which is very popular in the region, under control.
These pills appeared on the French market in the 90s and currently two million women consume them.
Without judging the French decision, the EMA has confirmed that after the study, the committee for the evaluation of risks in pharmacovigilance material, will give out a recommendation and will indicate whether the authorizations in the market should be modified, suspended or revoked, in the interests of all of the patients in the community.
A few days ago the Agency declared that the risks of blood clots are very low in all contraceptives; nevertheless, it admitted that the incidence rate is higher in the more modern drugs, with a frequency of between 20 and 40 cases per one hundred thousand.
Nonetheless, that organization, with headquarters in London, believes that these incidents are very rare and there is no reason to suspend their sale.
“If a drug is dangerous, and the relationship between risks and benefits is unfavourable, it should be suspended or withdrawn”, stated Jean-Paul Hamon, president of the Federation of Doctors of France, a syndicate of general practitioners and specialist liberals.
Along the same lines, Nathalie Bajos, from the National Institute of Health and Medical Investigation, said that we have to remember that no medicine exists with zero risks; even a common analgesic can lead to complications.
For many specialists, the risk of possible brain damage to those who consume these modern contraceptives is linked to other factors, like smoking, obesity or diabetes.
The issue generates concern, especially after the Mediator case, a product from the Servier laboratories for diabetes treatment that was withdrawn from market in 2009. Various studies support that Mediator is responsible for the death of around 500 people, as well as an undetermined number of people with cardiovascular and pulmonary damage.
Another recent health scandal was that of the breast implants Poly Implant Prothése (PIP), manufactured with a gel for industrial use instead of medical use.
With this history, it’s not a surprise that women abandon the use of these modern day contraceptives, in hope of r a profound investigation about their side effects.
(Translated by Jade Hewitt – Email: firstname.lastname@example.org)